Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.[2][3][4] Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL.[4] The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38.[5] This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.
Hairy cell leukemia (HCL) is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection.[4] HCL is named after these extra B cells which look “hairy” when viewed under a microscope.[4] As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced.[4]
^"Moxetumomab pasudotox (Lumoxiti) Use During Pregnancy". Drugs.com. 22 October 2018. Retrieved 20 April 2020.
^ abCite error: The named reference Lumoxiti FDA label was invoked but never defined (see the help page).
^ abCite error: The named reference Lumoxiti EPAR was invoked but never defined (see the help page).
^ abcdeCite error: The named reference FDA PR was invoked but never defined (see the help page).
Moxetumomabpasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory...
developed at the NIH. BL22 was superseded by moxetumomabpasudotox (HA22, CAT-8015). Moxetumomabpasudotox is approved in the EU and USA for treatment...
patients with HCL-classic or the Japanese variant. HA-22, now renamed moxetumomabpasudotox, is being studied in patients with relapsed hairy cell leukemia...
tested in humans with various forms of cancer. One of these, HA22 or Moxetumomabpasudotox (Moxe), targets CD22 on B cell malignancies; it has produced many...
targeting IL-13 for adults with moderate-to-severe atopic dermatitis". Moxetumomabpasudotox (CAT-3888) – CAT-3888 (formerly GCR-3888 and BL22) and CAT-8015...
Global Information
(what is this?) (verify)